Teva Pharmaceutical Industries Ltd. has received U.S. Food and Drug Administration approval for its Austedo Xr medication, which treats a range of uncontrollable muscle movements associated with Huntington's Disease.
The generic-drug maker said the FDA has approved Austedo Xr's extended-release tablets, a new once-daily formula for adults diagnosed with tardive dyskinesia and chorea.
Huntington's Disease is a rare and inherited progressive neurological disorder that causes nerve cells in parts of the brain to gradually break down and die.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.